RESULTS : Patients with ABCG2 421 CA or AA genotypes had 2.9 times greater odds of developing atorvastatin dose-dependent ADRs ( OR : 2.91 ; 95 % CI : 1.22-6 .95 ; p = 0.016 ) than those with ABCG2 421CC genotype .